Publication Cover
Reproductive Health Matters
An international journal on sexual and reproductive health and rights
Volume 3, 1995 - Issue 6: Women's health policies
103
Views
2
CrossRef citations to date
0
Altmetric
Original Articles

National women's health network and the US FDA: Two decades of activism

Pages 132-141 | Published online: 01 Nov 1995

References

  • H. Burkholz. The FDA Follies: An Alarming Look at Our Food and Drugs in the 1980s. 1994; Basic Books: New York.
  • B. Seaman. The Doctors' Case Against The Pill. 1969; McKay: New York.
  • C. Mann. Women's health research blossoms. Science. 11: 1995; 766–770. (Aug).
  • S.B. Ruzek. The Women's Health Movement. 1978; Praeger: New York.
  • D. Haire. How Safe is ‘Safe’?. 1981; National Women's Health Network: Washington DC.
  • Depo Provera: A Shot in the Dark. 1982Quebec Public Interest Research Group.
  • Network establishes Depo registry. Network News. 1979; 1–4. (July/Aug).
  • The Depo Provera debate. Network News. 1993; 8–10. (March/April).
  • M. Sun. Panel says Depo Provera not proved safe. Science. 23: 1984; 31–32. (Nov).
  • A. Davidson. Presentation at National Institutes of Child Health and Human Development Conference ‘Research on long acting contraception’. August.1995
  • Depo Provera form. Network News. 1993; 7. (May/June).
  • B. Seaman. Women and the Crisis in Sex Hormones. 1977; Bantam Books: New York.
  • R. Chalker. The Complete Cervical Cap Guide. 1987; Harper & Row: New York.
  • B. Seaman. Testimony before the US Senate Subcommittee on Health and Scientific Research. 1979. 1 August.
  • C. Pearson. Testimony before the FDA Obstetric and Gynecological Devices Advisory Panel. 1988. 24 February.
  • V. Leonard. Citizen Petition. 1988. 14 December.
  • Premarket testing guidelines for female barrier contraceptive devices also intended to prevent sexually transmitted diseases. 1990; US Food and Drug Administration.
  • J. Trussel, K. Sturgen, J. Stricker. Comparative contraceptive efficacy of the female condom and other barrier methods. Family Planning Perspectives. 26: 1994; 66–72.
  • A. Fugh-Berman, S. Epstein. Tamoxifen: disease prevention or disease substitution?. Lancet. 7: 1992; 1143–1145. (Nov).
  • T.J. Powles. The case for clinical trials of tamoxifen for prevention of breast cancer. Lancet. 7: 1992; 1145–1147. (Nov).
  • L.G. Ford. Breast cancer prevention on trial. Journal of Women's Health. 4(1): 1995; 11–12.
  • T.L. Bush, K.J. Helzlsouer. The role of tamoxifen in breast cancer. Treatment: yes, Prevention: no. Journal of Women's Health. 4(1): 1995; 13–14.
  • Breast cancer prevention study: Are healthy women put at risk by federally funded research?. Hearing before the Human Resources and Intergovernmental Relations Subcommittee of the US House of Representatives. 22 October 1992
  • J.S. Zones. The dangers of breast augmentation. Network News. 1989; 1–8. (July/Aug).
  • J.S. Zones. New developments in silicone breast implant regulation. Network News. 1991; 1–4. (June/July/Aug).
  • C. Pearson. Testimony before the FDA General and Plastic Surgical Devices Advisory Panel. 1991. 12 November.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.